The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.

CVS Health enters the second half of 2026 with stronger earnings and Aetna gains, but medical costs and Caremark risks cloud the recovery.

CVS Health's Q2 EPS jumps more than 40% as Health Care Benefits profitability improves, prompting a major boost to its 2026 AOI outlook.

Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.

Management had named the plan exits, the Medicare margin target and the repricing date before the run began.

Management has raised its full-year earnings outlook twice, and the segment doing most of the lifting is still short of its own target margin.

Cigna Group has lagged the broader market despite consistent earnings performance, while analysts remain moderately optimistic about its future prospects.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Cigna Group stock has delivered a 47.1% total return over the past 5 years, yet current valuation checks still lean toward the shares looking inexpensive rather than fully priced in. In light of recent earnings news and a steady long term track record, investors are weighing whether the recent price of US$282.49 already reflects this progress. Over 5 years, a 47.1% return suggests Cigna Group has rewarded patient shareholders while still inviting a closer look at whether the current price...

Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...